SCHEMBL15912499

SCHEMBL15912499

CCc1c[nH]c2cc(Br)ccc12

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.64
CHRNA7 P36544 1/20 0.64
CHRNA4 P43681 1/20 0.64
CYP2A6 P11509 1/20 0.54
GPR84 Q9NQS5 3/20 0.53
HTR2A P28223 2/20 0.47
TRPM8 Q7Z2W7 1/20 0.47
BCHE P06276 1/20 0.47
CSNK2A1 P68400 1/20 0.46
IMPDH2 P12268 1/20 0.46
MTNR1A P48039 1/20 0.46
MTNR1B P49286 1/20 0.46
SLC6A4 P31645 1/20 0.45
HTR2C P28335 1/20 0.44
IDO1 P14902 1/20 0.43
METAP2 P50579 1/20 0.43
CDK2 P24941 1/20 0.43
ADRB3 P13945 1/20 0.43
CFTR P13569 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1335521 0.85 GPR84 (0.73) CHRNB2CHRNA7CHRNA4GPR84HTR2A
SCHEMBL27929613 0.85 GPR84 (0.72) CHRNB2CHRNA7CHRNA4CYP2A6GPR84
SCHEMBL24144797 0.81 CHRNB2 (0.59) CHRNB2CHRNA7CHRNA4CYP2A6GPR84
SCHEMBL17024241 0.81 CYP2A6 (0.58) CHRNB2CHRNA7CHRNA4CYP2A6GPR84
SCHEMBL6031494 0.81 KDM4E (0.60) CHRNB2CHRNA7CHRNA4CYP2A6GPR84
SCHEMBL15897700 0.81 CHRNB2 (0.72) CHRNB2CHRNA7CHRNA4CYP2A6GPR84
SCHEMBL15897703 0.81 CHRNB2 (0.59) CHRNB2CHRNA7CHRNA4CYP2A6GPR84
SCHEMBL18036679 0.81 CHRNB2 (0.59) CHRNB2CHRNA7CHRNA4CYP2A6GPR84
SCHEMBL3197446 0.81 CHRNB2 (0.59) CHRNB2CHRNA7CHRNA4CYP2A6GPR84
SCHEMBL4484622 0.80 ALDH1A1 (0.56) CHRNB2CHRNA7CHRNA4CYP2A6GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688789-A1 MACROCYCLIC RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-11 EP disclosed
WO-2024211663-A9 MACROCYCLIC RAS INHIBITORS Revolution Medicines, Inc. (US) 2025-01-30 WO disclosed
US-20250002471-A1 6-SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. 2025-01-02 US disclosed
WO-2024211663-A1 CONDENSED MACROCYCLIC COMPOUNDS AS RAS INHIBITORS Revolution Medicines, Inc. (US) 2024-10-10 WO disclosed
US-20240059673-A1 SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. 2024-02-22 US disclosed
EP-4267559-A1 SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-11-01 EP disclosed
EP-4267560-A1 6-SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-11-01 EP disclosed
WO-2022140325-A1 6-SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-06-30 WO disclosed
WO-2022140326-A1 SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-06-30 WO disclosed
WO-2022140326-A1 SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-06-30 WO disclosed
WO-2022140325-A1 6-SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-06-30 WO disclosed
EP-3083588-B1 AROMATIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS SUNSHINE LAKE PHARMA CO LTD (CN) 2020-12-09 EP disclosed
US-9663498-B2 Aromatic heterocyclic compounds and their application in pharmaceuticals SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-05-30 US disclosed
EP-3083588-A1 AROMATIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS Sunshine Lake Pharma Co., Ltd. (CN) 2016-10-26 EP disclosed
US-20160251339-A1 AROMATIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-09-01 US disclosed
WO-2015090233-A1 AROMATIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-06-25 WO disclosed
US-20140213538-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213538-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 CHRNB2 1742/4885CHRNA7 1275/4885CHRNA4 1597/4885
US-20160251339-A1 AROMATIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS MAPT, APP, PSEN1 CHRNB2 193/4885CHRNA7 215/4885CHRNA4 301/4885
US-20250002471-A1 6-SUBSTITUTED INDOLE COMPOUNDS SSB, IDO1, IDO2 CHRNB2 4697/4885CHRNA7 4344/4885CHRNA4 4665/4885
US-20240059673-A1 SUBSTITUTED INDOLE COMPOUNDS SSB, IDO1, IDO2 CHRNB2 4723/4885CHRNA7 4587/4885CHRNA4 4752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.